▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Natalie Forbes

TMFBensTotum

Recent Articles by Natalie Forbes

patient treated by health professional at home

Sep 22, 2022 by Natalie Forbes

This Company Could Beat Out Teladoc, and It's Not Amazon

A potentially disruptive business model is finding its legs in the post-pandemic healthcare landscape.

doctor talking to senior man -- patient medical medicine healthcare

Sep 15, 2022 by Natalie Forbes

Why This Monster Stock's Recent Blunders Might Not Matter

Strong sales of its top blockbuster overcome some weaker pipeline results.

remote work from home laptop businesswoman

Sep 7, 2022 by Natalie Forbes

Merck's Deal With Seagen May Have Fallen Through. Now What?

A steep valuation may force Merck to look elsewhere for portfolio growth.

hospital surgery nurses prep bed

Sep 1, 2022 by Natalie Forbes

This Stock Soared in August. Is It Still a Buy?

This industry-leading company can weather a challenging operating environment.

GettyImages-1159345748

Aug 31, 2022 by Natalie Forbes

What This News Might Mean for Amgen

The company finds some protection against measures aimed to cut industry drug prices.

cosmetic treatment medical devices

Aug 21, 2022 by Natalie Forbes

Which Growth Stock Is a Better Buy Right Now -- AbbVie or InMode?

These beaten-down stocks share a favorable outlook for their aesthetic segments.

diabetes patient with continuous glucose monitor

Aug 17, 2022 by Natalie Forbes

How Eli Lilly Is Thinning Out the Competition

The company sees good market signals from its recently launched potential blockbuster drug.

diabetes patient with continuous glucose monitor

Aug 5, 2022 by Natalie Forbes

Should You Really Care About This Company's Short-Term Success?

Abbott Laboratories' growth looks much less impressive after removing sales from COVID-19 diagnostics.

doctors white coat healthcare

Aug 2, 2022 by Natalie Forbes

What 1 Key COVID Drug's News Might Mean For Pfizer

Oral antiviral Paxlovid saw stronger-than-expected sales in the first half of the year, but still hasn't captured the international markets.

person lab science research STEM

Jul 30, 2022 by Natalie Forbes

How This Multibillion-Dollar Company Is Shaking Off the Competition

The company has posted growth despite lower demand for several key products.

person standing on top of mountain empowered girl power

Jul 28, 2022 by Natalie Forbes

These New Blockbusters Could Fill Bristol-Myers Squibb's Revenue Gap

A looming patent cliff puts pressure on the company's newest products.

Surgeons perform robotic assisted surgery

Jul 24, 2022 by Natalie Forbes

How Medtronic Is Strengthening Its Robotics Portfolio

Advanced technology in spinal surgery is helping the company build its case in a fast-growing market.

doctors white coat healthcare

Jul 21, 2022 by Natalie Forbes

What This FDA Delay Means for Novartis

The FDA defers action on a highly anticipated potential blockbuster drug for cancer.

GettyImages-1167824509

Jul 21, 2022 by Natalie Forbes

How These Acquisitions Are Changing the Outlook for Bristol Myers Squibb

The company is reshaping and expanding its oncology portfolio.

Doctor consulting with pregnant patient

Jul 13, 2022 by Natalie Forbes

Why This Company Still Has a Long Runway for Growth

A competitive labor landscape makes this company's offerings even more attractive.

drug development pharmaceutical pharma research researchers doctors

Jul 11, 2022 by Natalie Forbes

How Its New Vaccine Could Propel GSK's Growth

GSK leads the race to deliver a vaccine for an untreated infectious disease.

Physician smiles at baby

Jul 9, 2022 by Natalie Forbes

This Company Could Ease the Pain in a Bear Market

New product candidates aim to diversify into areas with a large unmet medical need.

DNA sequence genetics test genomics

Jul 1, 2022 by Natalie Forbes

Why This Company Could See Long-Lasting Tailwinds Despite the Bear Market

An industry-leading company looks past COVID-19 to future growth.

Scientist working in lab

Jun 27, 2022 by Natalie Forbes

How Pfizer Plans to Unlock Another Mass-Market Vaccine

The company turns its attention to another infectious disease that lacks a vaccine.

covid booster vaccination syringe

Jun 25, 2022 by Natalie Forbes

Why Sanofi May Be a Frontrunner in Endemic COVID-19

There is a promising outlook for its next generation of vaccines.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services